Business
Medicure To Announce Fiscal Year End 2019 Financial Results on April 15, 2020
Medicure To Announce Fiscal Year End 2019 Financial Results on April 15, 2020 Cana...
About this update from Medicure Inc.
[{"type":"text","content":"\n\n\n\nMedicure To Announce Fiscal Year End 2019 Financial Results on April 15, 2020\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nWINNIPEG, April 13, 2020\n\n\n\nWINNIPEG, April 13, 2020 /CNW/ - Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the year ended December 31, 2019 on Wednesday, April 15, 2020. The financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Thursday, April 16, 2020 at 7:30 AM Central Time (8:30 AM Eastern Time).\nConference Call Info:\nTopic:  Medicure's Fiscal Year End 2019 Results\nCall date:  Thursday, April 16, 2020\nTime:  7:30 AM Central Time (8:30 AM Eastern Time)\nCanada toll: 1 (416) 764-8659\nNorth American toll-free:  1 (888) 664-6392\nPasscode:  not required\nWebcast: This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: http://www.medicure.com/investors   \nYou may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the Company's website.\nAbout Medicure Inc.Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin) tablets and the ReDS™ device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com. \nTo be added to Medicure's e-mail list, please visit: 
...